Cancer Research Cell Death Mechanisms and Cancer Therapy EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Drixler, T. A.
Right arrow Articles by Voest, E. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Drixler, T. A.
Right arrow Articles by Voest, E. E.
[Cancer Research 60, 1761-1765, March 15, 2000]
© 2000 American Association for Cancer Research

Tumor Biology

Continuous Administration of Angiostatin Inhibits Accelerated Growth of Colorectal Liver Metastases after Partial Hepatectomy1

Tom A. Drixler, Inne H. M. Borel Rinkes, Ewan D. Ritchie, Theo J. M. V. van Vroonhoven, Martijn F. B. G. Gebbink and Emile E. Voest2

Departments of Surgery [T. A. D., I. H. M. B. R., E. D. R., T. J. M. V. v. V.] and Internal Medicine [T. A. D., M. F. B. G. G., E. E. V.], Laboratory of Medical Oncology, University Medical Center Utrecht, 3584 CX Utrecht, the Netherlands

Human plasminogen-derived angiostatin is one of the most potent antiangiogenic agents currently known. However, it is unclear whether angiostatin is also effective against accelerated tumor growth induced by local up-regulation of growth factors, including angiogenesis stimulators, such as in regenerating liver. Prior to addressing this question, we tested, in mice, whether continuous administration of angiostatin could improve its biological effects. This assumption was based on the relatively short half-life of angiostatin in mice, as well as on the theoretical necessity to suppress tumor-induced angiogenesis continually. The findings presented here clearly indicate continuous administration to be superior to the conventional twice-daily bolus injections. Using the maximally effective regimen of 100 mg/kg/day via s.c. pump infusion, we found angiostatin to not only suppress s.c. primary tumors but also to significantly inhibit the outgrowth of colorectal hepatic metastases in resting liver and even to inhibit accelerated tumor growth in regenerating liver after 70% partial hepatectomy. In conclusion, angiostatin could play an important role in patients subjected to partial hepatectomy to prevent outgrowth of residual micrometastases, provided it is administered continuously to obtain maximal biological effects.




This article has been cited by other articles:


Home page
 JDRHome page
C.R. Dass, T.M.N. Tran, and P.F.M. Choong
Angiogenesis Inhibitors and the Need for Anti-angiogenic Therapeutics
Journal of Dental Research, October 1, 2007; 86(10): 927 - 936.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. M. Rademaker-Lakhai, L. V. Beerepoot, N. Mehra, S. A. Radema, R. van Maanen, J. S. Vermaat, E. O. Witteveen, C. M. Visseren-Grul, L. Musib, N. Enas, et al.
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Protein Kinase C {beta}-Inhibitor Enzastaurin in Combination with Gemcitabine and Cisplatin in Patients with Advanced Cancer
Clin. Cancer Res., August 1, 2007; 13(15): 4474 - 4481.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
X. Zhang, J. Xu, J. Lawler, E. Terwilliger, and S. Parangi
Adeno-Associated Virus-Mediated Antiangiogenic Gene Therapy with Thrombospondin-1 Type 1 Repeats and Endostatin
Clin. Cancer Res., July 1, 2007; 13(13): 3968 - 3976.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J. D.W. van der Bilt, M. E. Soeters, A. M.M.J. Duyverman, M. W. Nijkamp, P. O. Witteveen, P. J. van Diest, O. Kranenburg, and I. H.M. Borel Rinkes
Perinecrotic Hypoxia Contributes to Ischemia/Reperfusion-Accelerated Outgrowth of Colorectal Micrometastases
Am. J. Pathol., April 1, 2007; 170(4): 1379 - 1388.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
J. Michaud-Levesque, M. Demeule, and R. Beliveau
In vivo inhibition of angiogenesis by a soluble form of melanotransferrin
Carcinogenesis, February 1, 2007; 28(2): 280 - 288.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Kurup, C.-W. Lin, D. J. Murry, L. Dobrolecki, D. Estes, C. T. Yiannoutsos, L. Mariano, C. Sidor, R. Hickey, and N. Hanna
Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: a phase II study from Indiana University
Ann. Onc., January 1, 2006; 17(1): 97 - 103.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H.-K. Yu, J.-S. Kim, H.-J. Lee, J.-H. Ahn, S.-K. Lee, S.-W. Hong, and Y. Yoon
Suppression of Colorectal Cancer Liver Metastasis and Extension of Survival by Expression of Apolipoprotein(a) Kringles
Cancer Res., October 1, 2004; 64(19): 7092 - 7098.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Nakajima, T. Gotanda, H. Uchimiya, T. Furukawa, M. Haraguchi, R. Ikeda, T. Sumizawa, H. Yoshida, and S.-i. Akiyama
Inhibition of Metastasis of Tumor Cells Overexpressing Thymidine Phosphorylase by 2-Deoxy-L-Ribose
Cancer Res., March 1, 2004; 64(5): 1794 - 1801.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
H. E. Turner, A. L. Harris, S. Melmed, and J. A. H. Wass
Angiogenesis in Endocrine Tumors
Endocr. Rev., October 1, 2003; 24(5): 600 - 632.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. V. Beerepoot, E. O. Witteveen, G. Groenewegen, W. E. Fogler, B. K. L. Sim, C. Sidor, B. A. Zonnenberg, F. Schramel, M. F. B. G. Gebbink, and E. E. Voest
Recombinant Human Angiostatin by Twice-Daily Subcutaneous Injection in Advanced Cancer: A Pharmacokinetic and Long-Term Safety Study
Clin. Cancer Res., September 15, 2003; 9(11): 4025 - 4033.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Capillo, P. Mancuso, A. Gobbi, S. Monestiroli, G. Pruneri, C. Dell'Agnola, G. Martinelli, L. Shultz, and F. Bertolini
Continuous Infusion of Endostatin Inhibits Differentiation, Mobilization, and Clonogenic Potential of Endothelial Cell Progenitors
Clin. Cancer Res., January 1, 2003; 9(1): 377 - 382.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. H. M. Schellens and M. J. Ratain
Endostatin: Are the 2 Years Up Yet?
J. Clin. Oncol., September 15, 2002; 20(18): 3758 - 3760.
[Full Text] [PDF]

Home page
 JCOHome page
J. P. Eder Jr, J. G. Supko, J. W. Clark, T. A. Puchalski, R. Garcia-Carbonero, D. P. Ryan, L. N. Shulman, J. Proper, M. Kirvan, B. Rattner, et al.
Phase I Clinical Trial of Recombinant Human Endostatin Administered as a Short Intravenous Infusion Repeated Daily
J. Clin. Oncol., September 15, 2002; 20(18): 3772 - 3784.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. S. Herbst, K. R. Hess, H. T. Tran, J. E. Tseng, N. A. Mullani, C. Charnsangavej, T. Madden, D. W. Davis, D. J. McConkey, M. S. O'Reilly, et al.
Phase I Study of Recombinant Human Endostatin in Patients With Advanced Solid Tumors
J. Clin. Oncol., September 15, 2002; 20(18): 3792 - 3803.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
L. Hlatky, P. Hahnfeldt, and J. Folkman
Clinical Application of Antiangiogenic Therapy: Microvessel Density, What It Does and Doesn't Tell Us
J Natl Cancer Inst, June 19, 2002; 94(12): 883 - 893.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Streit, A. E. Stephen, T. Hawighorst, K. Matsuda, B. Lange-Asschenfeldt, L. F. Brown, J. P. Vacanti, and M. Detmar
Systemic Inhibition of Tumor Growth and Angiogenesis by Thrombospondin-2 Using Cell-based Antiangiogenic Gene Therapy
Cancer Res., April 1, 2002; 62(7): 2004 - 2012.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
T. A. Drixler, I. H. M. B. Rinkes, E. D. Ritchie, F. W. Treffers, T. J. M. V. van Vroonhoven, M. F. B. G. Gebbink, and E. E. Voest
Angiostatin Inhibits Pathological but Not Physiological Retinal Angiogenesis
Invest. Ophthalmol. Vis. Sci., December 1, 2001; 42(13): 3325 - 3330.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
O. Kisker, C. M. Becker, D. Prox, M. Fannon, R. D'Amato, E. Flynn, W. E. Fogler, B. K. L. Sim, E. N. Allred, S. R. Pirie-Shepherd, et al.
Continuous Administration of Endostatin by Intraperitoneally Implanted Osmotic Pump Improves the Efficacy and Potency of Therapy in a Mouse Xenograft Tumor Model
Cancer Res., October 1, 2001; 61(20): 7669 - 7674.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. S. Kerbel
Clinical Trials of Antiangiogenic Drugs: Opportunities, Problems, and Assessment of Initial Results
J. Clin. Oncol., September 15, 2001; 19(90001): 45s - 51.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
A. L. Feldman, H. R. Alexander, S. M. Hewitt, D. Lorang, C. E. Thiruvathukal, E. M. Turner, and S. K. Libutti
Effect of Retroviral Endostatin Gene Transfer on Subcutaneous and Intraperitoneal Growth of Murine Tumors
J Natl Cancer Inst, July 4, 2001; 93(13): 1014 - 1020.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Indraccolo, M. Morini, E. Gola, F. Carrozzino, W. Habeler, S. Minghelli, L. Santi, L. Chieco-Bianchi, Y. Cao, A. Albini, et al.
Effects of Angiostatin Gene Transfer on Functional Properties and in Vivo Growth of Kaposi's Sarcoma Cells
Cancer Res., July 1, 2001; 61(14): 5441 - 5446.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Guba, G. Cernaianu, G. Koehl, E. K. Geissler, K.-W. Jauch, M. Anthuber, W. Falk, and M. Steinbauer
A Primary Tumor Promotes Dormancy of Solitary Tumor Cells before Inhibiting Angiogenesis
Cancer Res., July 1, 2001; 61(14): 5575 - 5579.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
T. L. Moser, D. J. Kenan, T. A. Ashley, J. A. Roy, M. D. Goodman, U. K. Misra, D. J. Cheek, and S. V. Pizzo
Endothelial cell surface F1-FO ATP synthase is active in ATP synthesis and is inhibited by angiostatin
PNAS, May 24, 2001; (2001) 131067798.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
V. Stellmach, S. E. Crawford, W. Zhou, and N. Bouck
Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor
PNAS, February 27, 2001; 98(5): 2593 - 2597.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
T. L. Moser, D. J. Kenan, T. A. Ashley, J. A. Roy, M. D. Goodman, U. K. Misra, D. J. Cheek, and S. V. Pizzo
Endothelial cell surface F1-FO ATP synthase is active in ATP synthesis and is inhibited by angiostatin
PNAS, June 5, 2001; 98(12): 6656 - 6661.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.